Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Quest Diagnostics; Rosetta Genomics; GeneNews

NEW YORK (GenomeWeb News) – Quest Diagnostics this week said that its Simplexa Flu A/B & RSV Direct test has received the CE Mark and has been launched in Europe. The molecular test, developed by the firm's Focus Diagnostics business, runs on the 3M Integrated Cycler. The test uses a proprietary technique to eliminate nucleic-acid sample extraction, leading to faster results reporting, said Quest.


Rosetta Genomics has raised $1.5 million of its planned $1.9 million target in a private placement, according to documents filed with the US Securities and Exchange Commission. Last month the firm said that it had reached definitive agreements to place the common stock and warrants with investors.


GeneNews this week said that its shareholders have approved the proposed consolidation of the firm's issued and outstanding shares on the basis of one post-consolidation common share for every six pre-consolidation common shares. The Canadian molecular diagnostics firm has not set a definitive date for the reverse split, but said that it would take place no later than Jan. 31, 2012.

"We believe that this proposed share consolidation will provide shareholders with the potential for a more attractive share price, reduced shareholder transaction costs, and improved trading liquidity as our partners prepare to launch ColonSentry in their respective markets," GeneNews President and COO Gailina Liew said in a statement.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.